Skip to main content
DIMERIX LIMITED logo

DIMERIX LIMITED — Investor Relations & Filings

Ticker · DXB ISIN · AU000000DXB7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,124 across all filing types
Latest filing 2026-04-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX DXB

About DIMERIX LIMITED

https://dimerix.com/

Dimerix Limited focuses on the development of therapeutic treatments for inflammatory diseases, with a primary emphasis on kidney and respiratory conditions. The company utilizes its proprietary Receptor-Heteromer Investigation Technology (DMX-Technology) to identify and validate G protein-coupled receptor (GPCR) targets. Its lead candidate, DMX-200, is a chemokine receptor (CCR2) antagonist currently in Phase 3 clinical trials for the treatment of Focal Segmental Glomerulosclerosis (FSGS). The company is also advancing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD) and exploring applications for diabetic kidney disease. The core strategy involves targeting multiple signaling pathways simultaneously to address unmet medical needs in chronic inflammatory and fibrotic diseases.

Recent filings

Filing Released Lang Actions
Dimerix Quarterly Activities Report and Appendix 4C 10 pages 600.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Dimerix Quarterly Activities Report' and includes detailed operational updates, clinical trial progress, funding discussions, and financial cash flow data for the quarter ended 31 March 2026. It contains substantive financial data such as cash flows from operating activities, payments for research and development, and cash position at quarter end. The presence of an Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly financial report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content focuses on quarterly operational and financial performance rather than annual results or earnings highlights. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-29 English
ACTION3 Statistical Review Complete 4 pages 440.7KB
Regulatory Filings Classification · 95% confidence The document is a press release from Dimerix Limited announcing the completion of a blinded statistical review of their ACTION3 Phase 3 clinical trial data. It discusses clinical trial progress, regulatory feedback from the FDA, and strategic decisions regarding the trial's primary endpoint. The content focuses on clinical study updates, regulatory pathway considerations, and trial execution risk, without presenting actual financial statements or detailed financial performance data. It is not an earnings release, annual report, or interim financial report. The document is an announcement related to clinical trial progress and regulatory strategy rather than a formal regulatory filing or financial report. Given the nature of the content as a company announcement about clinical trial and regulatory updates, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-04-27 English
Dimerix Releases Investor Presentation and Video Recording 26 pages 3.5MB
Investor Presentation Classification · 95% confidence The document is titled as an "Investor Presentation" and includes detailed slides and commentary about the company's Phase 3 clinical trial, product pipeline, market opportunity, regulatory endpoints, and commercial partnerships. It is a comprehensive presentation aimed at investors, covering strategy, clinical data, and market positioning. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is not a brief announcement or a regulatory filing but a detailed presentation. Therefore, the document fits the category of an Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2026-04-27 English
Dimerix Singapore Investor Briefing 2 pages 346.1KB
Investor Presentation Classification · 95% confidence The document is a press release announcing an upcoming investor briefing event in Singapore, where the CEO will present updates on the company's clinical trial and growth strategy. It includes event details, RSVP instructions, and background information about the company and its clinical trial. There are no financial statements, detailed financial data, or regulatory filings included. The document is an announcement of an investor presentation event rather than the presentation itself or a financial report. Therefore, it fits best under the category of Investor Presentation (IP) as it focuses on presenting company updates and strategy to investors.
2026-04-08 English
Dimerix to Conduct Review of ACTION3 Statistical Assumptions 3 pages 390.7KB
Regulatory Filings Classification · 95% confidence The document is a press release from Dimerix Limited announcing a blinded review of statistical assumptions for their Phase 3 clinical trial ACTION3. It discusses study design, regulatory interactions with the FDA, and upcoming data review timelines. There are no financial statements, earnings data, or detailed financial analysis. The content focuses on clinical trial progress and regulatory compliance rather than financial results or management changes. It is not a full annual or interim report, nor an earnings release or management discussion. The document is an update on clinical trial status and regulatory process, typical of a Regulatory Filing (RNS) as it does not fit other specific categories like Capital Update or Legal Proceedings. The length is moderate and the content is an announcement rather than a detailed report or presentation.
2026-03-15 English
Dimerix Presents at Euroz Hartleys Institutional Conference 28 pages 3.8MB
Investor Presentation Classification · 95% confidence The document is a press release announcing that Dimerix Limited's CEO will present at the Euroz Hartleys Institutional Conference 2026. It includes a detailed investor presentation about the company's Phase 3 clinical trial for a kidney disease drug, covering clinical trial design, commercial strategy, and scientific background. The text mentions that a copy of the presentation is attached, and the content is focused on providing detailed information to investors about the company's clinical development and growth strategy. The document is approximately 15,000 characters, indicating it is a full presentation rather than a brief announcement. There is no indication that this is an earnings release, annual report, or regulatory filing. The content aligns with an Investor Presentation (IP) as it provides detailed financial and strategic information for investors at a conference. Therefore, the appropriate classification is Investor Presentation (IP).
2026-03-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.